Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: We aim to evaluate the effects of auranofin, a known antioxidant, on hepatic steatosis, inflammation, and fibrosis, contributing to non-alcoholic steatohepatitis (NASH) development in vivo and in vitro. Methods: Transcriptome analysis of LX-2 cells was that expression patterns of genes changed by auranofin, and their related pathways were estimated. We used the gene set enrichment analysis (GSEA) program to determine the pathway involved in overall genetic change. In vitro, LX-2 and HepG2 cells were treated with transforming growth factor (TGF)-β1 and palmitic acid (PA), respectively, and the antifibrotic and antiadipogenic effect function of auranofin was evaluated. Results: Transcriptome analysis revealed that auranofin decreased the expression of 15 genes, including thrombospondin 1, endothelin 1 (ET-1), fibronectin 1, and LOX. The molecular functions of these genes are involved in collagen binding. GSEA of the overall gene expression pattern revealed that many genes increased in the reactive oxygen species pathway and decreased in the inflammatory response. Auranofin decreased nuclear factor kappa B (NF-κB) and IκBα in TGF-β1-induced LX-2 cells, thereby reducing ET-1 and fibrosis. Furthermore, increased pNRF2 in PA-induced HepG2 cells led to increased antioxidant marker expression and decreased lipid accumulation. In the bile duct ligation model mice, auranofin reduced the fibrosis area and increased the survival rate. Auranofin reduced liver fibrosis and lipid accumulation in NASH model mice fed on a Western diet. Conclusions: Auranofin inhibits lipogenesis and fibrosis formation and is a proposed candidate for NASH treatment.
Abstract
Background/Aims: We aim to evaluate the effects of auranofin, a known antioxidant, on hepatic steatosis, inflammation, and fibrosis, contributing to non-alcoholic steatohepatitis (NASH) development in vivo and in vitro. Methods: Transcriptome analysis of LX-2 cells was that expression patterns of genes changed by auranofin, and their related pathways were estimated. We used the gene set enrichment analysis (GSEA) program to determine the pathway involved in overall genetic change. In vitro, LX-2 and HepG2 cells were treated with transforming growth factor (TGF)-β1 and palmitic acid (PA), respectively, and the antifibrotic and antiadipogenic effect function of auranofin was evaluated. Results: Transcriptome analysis revealed that auranofin decreased the expression of 15 genes, including thrombospondin 1, endothelin 1 (ET-1), fibronectin 1, and LOX. The molecular functions of these genes are involved in collagen binding. GSEA of the overall gene expression pattern revealed that many genes increased in the reactive oxygen species pathway and decreased in the inflammatory response. Auranofin decreased nuclear factor kappa B (NF-κB) and IκBα in TGF-β1-induced LX-2 cells, thereby reducing ET-1 and fibrosis. Furthermore, increased pNRF2 in PA-induced HepG2 cells led to increased antioxidant marker expression and decreased lipid accumulation. In the bile duct ligation model mice, auranofin reduced the fibrosis area and increased the survival rate. Auranofin reduced liver fibrosis and lipid accumulation in NASH model mice fed on a Western diet. Conclusions: Auranofin inhibits lipogenesis and fibrosis formation and is a proposed candidate for NASH treatment.
참고문헌 (40)
- Musso G, "Non-alcoholic steatohepatitis : emerging molecular targets and therapeutic strategies", Nat Rev Drug Discov, 15, pp.249~274 (2016)
- Chalasani N, "The diagnosis and management of non-alcoholic fatty liver disease : practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology", Gastroenterology, 142, pp.1592~1609 (2012)
- Hwangbo H, "Auranofin attenuates non-alcoholic fatty liver disease by suppressing lipid accumulation and NLRP3 Inflammasome-mediated hepatic inflammation in vivo and in vitro", Antioxidants(Basel), 9, pp.1040~ (2020)
- Nam HH, "Osthol attenuates hepatic steatosis via decreased triglyceride synthesis not by insulin resistance", World J Gastroenterol, 20, pp.11753~11761 (2014)
- Chalasani N, "The diagnosis and management of non-alcoholic fatty liver disease : practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association", Hepatology, 55, pp.2005~2023 (2012)
- Haas JT, "Pathophysiology and mechanisms of nonalcoholic fatty liver disease", Annu Rev Physiol, 78, pp.181~205 (2016)
- Adams LA, "The histological course of nonalcoholic fatty liver disease : a longitudinal study of 103 patients with sequential liver biopsies", J Hepatol, 42, pp.132~138 (2005)
- Van Herck MA, "Animal models of nonalcoholic fatty liver disease-a starter’s guide", Nutrients, 9, pp.1072~ (2017)
- Betteridge DJ, "What is oxidative stress", Metabolism (2000)
- Casas-Grajales S, "Antioxidants in liver health", World J Gastrointest Pharmacol Ther, 6, pp.59~72 (2015)
- Yoshikawa T, "What is oxidative stress?", Jpn Med Assoc J, 45, pp.271~276 (2002)
- Ma Q, "Role of NRF2 in oxidative stress and toxicity", Annu Rev Pharmacol Toxicol, 53, pp.401~426 (2013)
- Moi P, "Isolation of NF-E2-related factor 2(Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2", AP1 repeat of the beta-globin locus control region, 1994, pp.91, 9926~9930
- Kaspar JW, "Nrf2 : INrf2(Keap1)signaling in oxidative stress", Free Radic Biol Med, 47, pp.1304~1309 (2009)
- Xu D, "The role of Nrf2in liver disease : novel molecular mechanisms and therapeutic approaches", Front Pharmacol, 9, pp.1428~ (2019)
- Alam J, "Nrf2, a Cap’n’Collar transcription factor, regulates induction of the heme oxygenase-1 gene", J Biol Chem, 274, pp.26071~26078 (1999)
- Bellezza I, "Nrf2-Keap1 signaling in oxidative and reductive stress", Biochim Biophys Acta Mol Cell Res, 1865, pp.721~733 (2018)
- Hennig P, "The crosstalk between Nrf2 and inflammasomes", Int J Mol Sci, 19, pp.562~ (2018)
- Vomund S, "Nrf2, the master regulator of anti-oxidative responses", Int J Mol Sci, 18, pp.2772~ (2017)
- Klaassen CD, "Nrf2 the rescue : effects of the antioxidative", electrophilic response on the liver, 2010, pp.244, 57~65
- Reddy NM, "The triterpenoid CDDO-imidazolide confers potent protection against hyperoxic acute lung injury in mice", Am J Respir Crit Care Med, 180, pp.867~874 (2009)
- Sussan TE, "Targeting Nrf2 with the triterpenoid CDDOimidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice", Proc Natl Acad Sci U S A, 106, pp.250~255 (2009)
- Thimmulappa RK, "Preclinical evaluation of targeting the Nrf2pathway by triterpenoids(CDDO-Im and CDDO-Me)for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils", Antioxid Redox Signal, 9, pp.1963~1970 (2007)
- Bataille AM, "Nrf2 : a potential target for new therapeutics in liver disease", Clin Pharmacol Ther, 92, pp.340~348 (2012)
- Bombardier C, "Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial", Am J Med, 81, pp.565~578 (1986)
- Casini A, "Medicinal Chemistry of Gold Anticancer Metallodrugs", Walter de Gruyter (2018)
- Madeira JM, "The biological activity of auranofin : implications for novel treatment of diseases", Inflammopharmacology, 20, pp.297~306 (2012)
- Locy ML, "Thioredoxin reductase inhibition elicits Nrf2-mediated responses in Clara cells : implications for oxidant-induced lung injury", Antioxid Redox Signal, 17, pp.1407~1416 (2012)
- Staples S, "Selenium-independent antioxidant and anti-inflammatory effects of thioredoxin reductase inhibition in alveolar macrophages", Life Sci, 259, pp.118285~ (2020)
- Kye-ImJeon, "Gold compound auranofin inhibits IκB kinase (IKK) by modifying Cys-179 of IKKβ subunit", Experimental and Molecular Medicine, 35(2), pp.61~66 (2003), 생화학분자생물학회
- Kim NH, "Auranofin, a gold(I)-containing antirheumatic compound, activates Keap1", Nrf2 signaling via Rac1, J Pharmacol Sci, pp.2010, 113[DOI]
- Lee DF, "KEAP1 E3ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta", Mol Cell, 36, pp.131~140 (2009)
- Banning A, "NF-kappaB, Nrf2, and HO-1 interplay in redox-regulated VCAM-1 expression", Antioxid Redox Signal, 7, pp.889~899 (2005)
- Brigelius-Flohé R, "Basic principles and emerging concepts in the redox control of transcription factors", Antioxid Redox Signal, 15, pp.2335~2381 (2011)
- Wakabayashi N, "When NRF2 talks, who’s listening?", Antioxid Redox Signal, 13, pp.1649~1663 (2010)
- Häcker H, "Regulation and function of IKK and IKKrelated kinases", Sci STKE (2006)
- Brunt EM, "Histopathology of non-alcoholic fatty liver disease", Clin Liver Dis, 13, pp.533~544 (2009)
- Schwabe RF, "Mechanisms of fibrosis development in nonalcoholic steatohepatitis", Gastroenterology, 158, pp.1913~1928 (2020)
- Bai J, "Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans", EBioMedicine, 57, pp.102849~ (2020)
- Lu JW, "Overexpression of endothelin 1 triggers hepatocarcinogenesis in zebrafish and promotes cell proliferation and migration through the AKT pathway", PLoS One, 9, pp.e85318~ (2014)